Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Neonc Technologies, Inc.
Eli Lilly and Company
Massive Bio, Inc.
RefleXion Medical
Taproot Health